DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Aveed is a drug marketed by Endo Pharms Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-two patent family members in thirty-eight countries.
The generic ingredient in AVEED is testosterone undecanoate. There are sixty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the testosterone undecanoate profile page.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 14, 2027. This may change due to patent challenges or generic licensing.
There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There are two tentative approvals for the generic drug (testosterone undecanoate), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
Summary for AVEED
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||45|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for AVEED|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for AVEED|
|What excipients (inactive ingredients) are in AVEED?||AVEED excipients list|
|DailyMed Link:||AVEED at DailyMed|
DrugPatentWatch® Estimated Generic Entry Opportunity Date for AVEED
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Endo Pharms Inc||AVEED||testosterone undecanoate||INJECTABLE;INTRAMUSCULAR||022219-001||Mar 5, 2014||RX||Yes||Yes||Get Started Free||Get Started Free||Get Started Free|
|Endo Pharms Inc||AVEED||testosterone undecanoate||INJECTABLE;INTRAMUSCULAR||022219-001||Mar 5, 2014||RX||Yes||Yes||Get Started Free||Get Started Free||Y||Get Started Free|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|